Thromboprophylaxis in the Morbidly Obese With Weight Based Dosing of Fondaparinux: A Pharmacodynamic Study.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Fondaparinux sodium (Primary)
- Indications Deep vein thrombosis
- Focus Therapeutic Use
- 23 Feb 2016 Biomarkers information updated
- 11 Aug 2009 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 27 Jan 2009 Planned end date changed from 1 Aug 2017 to 1 Jan 2009 as reported by ClinicalTrials.gov.